UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to_________ Commission File Number: 001-01011 ♥CVSHealth CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 17, 2024 CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-01011 05-0494040 (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.) One CVS Drive Woonsocket, Rhode Island 02895 (Address of Principal Ex ...

CVS Health on Wednesday reported mixed third-quarter results as higher medical costs squeezed its bottom line. The earnings report is CEO David Joyner's first at the helm of the troubled retail drugstore chain. The company expects elevated medical costs to continue to pressure its performance this year, "and as a result we are not providing a formal outlook at this time," a spokesperson told CNBC. CVS will provide commentary on what it expects "directionally" during its earnings call, the spokesperson said. ...

Executive Appointments - CVS Health CEO David Joyner promoted Prem Shah to group president, overseeing CVS Caremark, CVS Pharmacy, and healthcare delivery businesses [1][6] - Steve Nelson, former UnitedHealth Group executive, was hired to lead Aetna, the nation's third-largest health insurer [1][8] Financial Performance - CVS Health reported Q3 2025 net income of $87 million, a significant decline from $2.2 billion in Q3 2024 [2] - Revenues increased 6% to $95 billion in Q3 2025, but profits dropped due to a $1.1 billion premium deficiency reserve in the health care benefits segment [4] Business Challenges - CVS Health faces cost control challenges in its Aetna health insurance business and retail pharmacies, contributing to a declining share price [3] - Medicare Advantage plans are under pressure due to increased healthcare utilization by seniors post-COVID-19 pandemic [4] Strategic Focus - CVS Health is committed to its diversified portfolio, including drugstores, outpatient services, primary care clinics, Caremark pharmacy benefit management, and Aetna with 27 million medical members [5] - The company aims to improve financial and operational performance through its integrated business model under new leadership [8][9]

Prem Shah named Group President, CVS Health; Steve Nelson named President, AetnaWOONSOCKET, R.I., Nov. 6, 2024 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced Prem Shah will be Group President, and will continue to report to David Joyner, President and Chief Executive Officer. In addition, the company announced the appointment of Steve Nelson as President, Aetna, and he will also report to Joyner. Both appointments are effective today.As Group President, Shah will be responsible for the operational p ...

Financial Highlights Third quarter total revenues increased to $95.4 billion, up 6.3% compared to the prior year Third quarter GAAP diluted EPS of $0.07 and Adjusted EPS of $1.09 Third quarter GAAP diluted EPS and Adjusted EPS include charges to record premium deficiency reserves of approximately $1.1 billion ($0.63 per share) in the Health Care Benefits segment Generated year-to-date cash flow from operations of $7.2 billion CEO Commentary "Our integrated model accelerates our ability to uniquely do what i ...

Key TakeawaysCVS Health is scheduled to report earnings Wednesday morning after two disappointing quarters to start 2024.Shares have fallen roughly 30% since the start of 2024, but analysts largely believe CVS will be able to recover some of its stock losses going forward.Last month, the pharmacy chain and health-care provider faced reports that it was considering breaking up its business and installed a new CEO. CVS Health (CVS) will report third-quarter earnings before the market opens Wednesday after the ...

Wall Street analysts forecast that CVS Health (CVS) will report quarterly earnings of $1.57 per share in its upcoming release, pointing to a year-over-year decline of 29%. It is anticipated that revenues will amount to $92.87 billion, exhibiting an increase of 3.5% compared to the year-ago quarter.The current level reflects an upward revision of 5.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their ...

Core Viewpoint - CVS Health is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending September 2024, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The earnings report is scheduled for November 6, 2024, and could lead to a stock price increase if the results exceed expectations, while a miss could result in a decline [2]. - The consensus estimate for CVS Health's quarterly earnings is $1.57 per share, reflecting a 29% decrease year-over-year, with expected revenues of $92.87 billion, marking a 3.5% increase from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 5.13% higher, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for CVS Health is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -12.28%, suggesting a bearish outlook from analysts [10]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, with positive readings being more reliable [5][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically shown a nearly 70% chance of delivering a positive surprise [8]. Historical Performance - CVS Health has beaten consensus EPS estimates three out of the last four quarters, with a recent surprise of +5.17% when it reported earnings of $1.83 per share against an expectation of $1.74 [11][12]. Conclusion - CVS Health does not currently appear to be a strong candidate for an earnings beat, and investors should consider other factors when making decisions regarding the stock ahead of the earnings release [15].

In the latest trading session, CVS Health (CVS) closed at $56.25, marking a -1.94% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.16%. Elsewhere, the Dow lost 0.37%, while the tech-heavy Nasdaq added 0.78%.The the stock of drugstore chain and pharmacy benefits manager has fallen by 8.78% in the past month, lagging the Retail-Wholesale sector's loss of 0.07% and the S&P 500's gain of 1.67%.Investors will be eagerly watching for the performance of CVS Health in it ...